Doximity is trading 4.52% down at $25.16 after Freedom Capital downgraded the stock from Buy to Hold on September 8, 2026, citing margin concerns and limited near-term upside after its post-earnings rally.
- Freedom Capital raised its price target to $27 from $24.
- The downgrade appears to have pressured shares at the open.
- Broader markets are relatively subdued, making the analyst action the clearest identified catalyst.